Tiziana Life Sciences Employee Directory
Biotechnology ResearchEngland, United Kingdom11-50 Employees
Tiziana Life Sciences is a UK-based biotechnology company focused on discovering and developing novel molecules to treat human diseases, with an emphasis on oncology and immunology. Its lead candidate, milciclib, targets cyclin-dependent kinases and other protein kinases to interfere with cell division, and it is in Phase II clinical trials for thymic carcinoma in patients who have previously received chemotherapy. The company is also advancing foralumab, a fully human anti-CD3 antibody, which is in Phase II development for autoimmune and inflammatory diseases such as ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. In addition, Tiziana is pursuing an intranasal formulation of foralumab for potential therapeutic applications in neurological conditions, reflecting its exploration of diverse immunomodulatory approaches. Based in London, the company operates within the biotechnology research sector and engages in clinical development to address unmet medical needs.